CLNN
Clene Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.35
+4.82%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$4.23
From 52W high−65.20%
Volume191431.00
Market cap$61.20M
P/E (TTM)—
P/S (TTM)310.6x
Div yield—
Key dataSep 18, 2026
Open
$4.23
From 52W high
−65.20%
Volume
191431.00
Market cap
$61.20M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.7x
P/E (TTM)
—
RSI (14)
53.4
MomentumView details →
1D Return
+4.82%
YTD Return
−25.47%
SummaryUpdated Jun 1, 2026
Clene Inc. (NASDAQ:CLNN) is a clinical-stage pharmaceutical company founded in 2013 and headquartered in Salt Lake City, Utah. The company went public in October 2018 and focuses on developing novel nanotechnology-based therapeutics for treating neurodegenerative diseases. Clene specializes in clean-surfaced nanotechnology (CSN) therapeutics, with its lead drug candidate CNM-Au8 currently in multiple clinical trials for conditions including amyotrophic lateral sclerosis (ALS), multiple sclerosis, and Parkinson's disease. The company operates in the biotechnology sector within the broader healthcare industry.
Similar companies
Latest newsMore news →
Clene Inc. priced a $4 million registered direct offering of 1,219,513 shares at $3.28 per share to existing shareholders, including insiders.5d agoClene Inc. reported a quarterly loss of $0.6 per share for Q2 2026, missing the Zacks Consensus Estimate of a loss of $0.37, but beating revenue estimates.37d agoClene announced it will submit a new drug application (NDA) for CNM-Au8 as an ALS treatment in early Q4 2026, following FDA meetings.39d ago